Daratumumab for refractory immune‐mediated thrombotic thrombocytopenic purpura.

Keywords: daratumumab; plasma cell; refractory; thrombotic thrombocytopenic purpura (TTP) EN daratumumab plasma cell refractory thrombotic thrombocytopenic purpura (TTP) 429 433 5 07/14/23 20230715 NES 230715 INTRODUCTION Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-threatening condition usually associated with IgG antibody-mediated destruction of the disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) enzyme. ADAMTS13 activity was typically performed within 24 h of sample collection, whereas ADAMTS13 antigen and anti-ADAMTS13 IgG antibody titres were analysed in batches, delaying incorporation of the results into the clinical management. ADAMTS13 activity B ( b TECHNOZYM® ADAMTS13 Activity ELISA Kit), ADAMTS13 antigen (TECHNOZYM® ADAMTS13 Antigen ELISA Kit) and anti-ADAMTS13 IgG antibody titres (TECHNOZYM® ADAMTS13 INH ELISA Kit) were determined by ELISA method. Both had a reduction in anti-ADAMTS13 IgG antibody titres after daratumumab and had negative anti-ADAMTS13 IgG antibody titres by 90 days. [Extracted from the article]